References
- Charles PGP, Ward PB, Johnson PDR, Howden BP, Grayson ML. Clinical features associated with bacteraemia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38:448–451
- Howden BP, Ward PB, Charles PGP, et al. Treatment outcomes for serious infections caused by methicillin resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521–528
- Larsen AR, Bocher S, Steger M, Goering RV, Pallesen LV, Skov R. Epidemiology of European community-associated methicillin-resistant Staphylococcus aureus clonal complex 80 type IV strains isolated in Denmark from 1993 to 2004. J Clin Microbiol 2008; 46: 62–68
- Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RCJ, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteraemia. J Clin Microbiol 2004; 42: 2398–2402
- Tenover FCJ, Biddle W, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001, 7: 327–332.
- Tenover FC, Moellering RCJ. The rationale for revising the clinical and laboratory standards institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007, 44: 1208–1215
- Walsh TR, Bolmström A, Qwärnström A, et al. Evaluation of Current Methods for Detection of Staphylococci with Reduced Susceptibility to Glycopeptides. J Clin Microbiol 2001; 39: 2439–2444
- CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement CLSI document M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute; 2010
- Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AR. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. JAntimicrob Chemother 2001; 47:399–403